172 related articles for article (PubMed ID: 19029224)
1. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.
Carlomagno F; Guida T; Anaganti S; Provitera L; Kjaer S; McDonald NQ; Ryan AJ; Santoro M
Endocr Relat Cancer; 2009 Mar; 16(1):233-41. PubMed ID: 19029224
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
[TBL] [Abstract][Full Text] [Related]
3. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
[TBL] [Abstract][Full Text] [Related]
5. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Vidal M; Wells S; Ryan A; Cagan R
Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
[TBL] [Abstract][Full Text] [Related]
6. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Carlomagno F; Guida T; Anaganti S; Vecchio G; Fusco A; Ryan AJ; Billaud M; Santoro M
Oncogene; 2004 Aug; 23(36):6056-63. PubMed ID: 15184865
[TBL] [Abstract][Full Text] [Related]
7. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
8. Structure and chemical inhibition of the RET tyrosine kinase domain.
Knowles PP; Murray-Rust J; Kjaer S; Scott RP; Hanrahan S; Santoro M; Ibáñez CF; McDonald NQ
J Biol Chem; 2006 Nov; 281(44):33577-87. PubMed ID: 16928683
[TBL] [Abstract][Full Text] [Related]
9. A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.
Sala E; Mologni L; Cazzaniga S; Papinutto E; Gambacorti-Passerini C
Int J Biol Macromol; 2006 Aug; 39(1-3):60-5. PubMed ID: 16490247
[TBL] [Abstract][Full Text] [Related]
10. A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.
Iwashita T; Murakami H; Kurokawa K; Kawai K; Miyauchi A; Futami H; Qiao S; Ichihara M; Takahashi M
Biochem Biophys Res Commun; 2000 Feb; 268(3):804-8. PubMed ID: 10679286
[TBL] [Abstract][Full Text] [Related]
11. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.
Carlomagno F; Santoro M
J Chemother; 2004 Nov; 16 Suppl 4():49-51. PubMed ID: 15693160
[TBL] [Abstract][Full Text] [Related]
12. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
13. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
14. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.
Beaudry P; Nilsson M; Rioth M; Prox D; Poon D; Xu L; Zweidler-Mckay P; Ryan A; Folkman J; Ryeom S; Heymach J
Mol Cancer Ther; 2008 Feb; 7(2):418-24. PubMed ID: 18245671
[TBL] [Abstract][Full Text] [Related]
15. A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nakaoku T; Kohno T; Araki M; Niho S; Chauhan R; Knowles PP; Tsuchihara K; Matsumoto S; Shimada Y; Mimaki S; Ishii G; Ichikawa H; Nagatoishi S; Tsumoto K; Okuno Y; Yoh K; McDonald NQ; Goto K
Nat Commun; 2018 Feb; 9(1):625. PubMed ID: 29434222
[TBL] [Abstract][Full Text] [Related]
16. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
[TBL] [Abstract][Full Text] [Related]
17. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
19. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.
Newton R; Bowler KA; Burns EM; Chapman PJ; Fairweather EE; Fritzl SJR; Goldberg KM; Hamilton NM; Holt SV; Hopkins GV; Jones SD; Jordan AM; Lyons AJ; Nikki March H; McDonald NQ; Maguire LA; Mould DP; Purkiss AG; Small HF; Stowell AIJ; Thomson GJ; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
Eur J Med Chem; 2016 Apr; 112():20-32. PubMed ID: 26874741
[TBL] [Abstract][Full Text] [Related]
20. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Arao T; Fukumoto H; Takeda M; Tamura T; Saijo N; Nishio K
Cancer Res; 2004 Dec; 64(24):9101-4. PubMed ID: 15604279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]